TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Reintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. have a spouse who participated in OEF/OIF and is at least 1 month post-deployment;~2. if not married, must have lived as married for at least one year;~3. live with the service member when not deployed;~4. have been a spouse/significant other throughout the service member's deployment period;~5. and have a telephone.~Exclusion Criteria:~1. current diagnosis of schizophrenia or other major mental illness;~2. auditory impairment that would make telephone use difficult; or~3. service member refusal of assent for spouse to participate.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telephone support (Type: EXPERIMENTAL): 12 telephone support group sessions based on the letters of the word BATTLEMIND

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-90 years old~* Scheduled for cardiac surgery requiring cardiopulmonary bypass~Exclusion Criteria:~* Off-pump surgical procedures~* Anticipated deep hypothermic circulatory arrest~* In available, baseline cardiac troponin I (\>0.5 ng/L) or troponin T (\> 0.1 ng/mL) levels (at RVH or CC, respectively)~* Any contraindications to the proposed interventions~* Active infection, including patients with endocarditis or infected pacemaker leads.~* Any infection requiring long- term antibiotics ( \> 14 days)~* kidney disease requiring renal replacement therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Hyperinsulinemic-normoglycemic clamp (Type: EXPERIMENTAL): Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
- Insulin at the standard of care levels (Type: OTHER): Group B will be administered insulin at the standard of care levels established by the participating institution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Predictors of Antidepressant Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Inclusion criteria will include:~* Participants diagnosed with Major Depressive Disorder and will include Hamilton Depressive Rating Scale (HDRS) scores \>15~Exclusion Criteria:~* Comorbid conditions that are medical, neurological or psychiatric, pregnancy, use of hormones (including birth control) or use of psychotropic agents~* We will only permit certain past anxiety disorder diagnoses, including generalized anxiety, panic, agoraphobia, social phobia~* We also will exclude left-handed individuals and patients who have used any centrally acting medications or recreational drugs with the past 2 months~* No history of an implant, pacemaker or pacemaker wires, open heart surgery, artificial heart valve, brain aneurysm surgery, middle ear implant, hearing aid, braces or extensive dental work, cataract surgery or lens implant, implanted mechanical or electrical device, or artificial limb or joint~* No metallic object in their body (such as braces) or have a history of foreign metallic object in the body such as bullets, BB's, pellets, shrapnel, or other metal fragments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Known Placebo First (Type: EXPERIMENTAL): This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated.
- Active (blinded) Placebo first group (Type: EXPERIMENTAL): This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who had received at least one dose of the study vaccine in the primary study (103860/064)~* Written informed consent obtained from each subject before each blood sampling visit

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- HBV-1 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
- HBV-2 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
- HBV-3 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
- HBV-4 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
- HBV-5 Group (Type: EXPERIMENTAL): neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
- HBV-6 Group (Type: EXPERIMENTAL): neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Male or female and greater than or equal to 12 years of age;~2. Have a diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures~3. Participants with computed tomography (CT) or magnetic resonance imaging (MRI) diagnosis within the last 10 years (for adults) and 5 years (for adolescents) prior to visit 1 that ruled out progressive central nervous system (CNS) disorders, example, neurodegenerative disorders, brain tumors. For participants without existing CT or MRI results, CT or MRI was performed at or after Visit 1 but results evaluation was performed by Visit 2~4. Participants who had been treated for at least 12 weeks but confirmed to be uncontrolled with more than one standard antiepileptic drug (AED) for 2 years before enrollment~5. During the 6-week Prerandomization Phase participants must have had greater than or equal to 5 partial seizures per 6-week~6. Are currently being treated with stable doses and administrations of 1, 2, or a maximum of 3 approved AEDs. Only 1 inducer AED (defined as carbamazepine, phenytoin or oxcarbazepine only) out of the maximum of 3 AEDs is allowed~Exclusion Criteria~1. Presence of nonmotor simple partial seizures only;~2. Presence of primary generalized epilepsies or seizures, such as absences and/or myoclonic epilepsies;~3. Presence or previous history of Lennox-Gastaut syndrome;~4. A history of status epilepticus within 1 year prior to screening~5. Seizure clusters where individual seizures cannot be counted~6. A history of psychogenic seizures within 5 years prior to screening

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD~Exclusion Criteria:~* History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium 200 μg once-daily (Type: EXPERIMENTAL): Aclidinium bromide 200 μg once-daily by inhalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ubiquinol (Reduced COQ10) for Patients With Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years old~* Suspected or confirmed infection~* Presence of 2 or more systemic inflammatory response syndrome (SIRS) criteria~* Admission to the ICU~Exclusion Criteria:~* Under 18 years old~* Current CoQ10 supplementation~* Unable to receive enteral medications~* Would need a nasogastric or orogastric tube solely for the purposes of the study~* Pregnancy, incarceration, mentally disability~* Patient confirmed Comfort measures only, Do not resuscitate (DNR) and/or Do not intubate. Patients with DNR but intubated and being provided full care are eligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
- Ubiquinol (Type: EXPERIMENTAL): Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female volunteers between 18 and 50 years requiring contraception~Exclusion Criteria:~* Pregnancy or lactation~* Any conditions that might interfere with the outcome as well as all contraindications for OC use

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant patients~* live singleton pregnancy~Exclusion Criteria:~* BMI \>40~* obstructive sleep apnea~* drug abuse~* chronic pain~* chronic opioid use~* nonfunctioning epidural

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 2 percent Lidocaine with epinephrine and epidural morphine (Type: ACTIVE_COMPARATOR): None
- 3 percent 2-Chloroprocaine and epidural morphine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Participant has an established diagnosis of multiple myeloma based on the myeloma diagnostic criteria.~* Participant has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen.~* Participant must have adequate organ function.~Exclusion criteria:~* Participant has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy.~* Participant has known hypersensitivity to any components of bortezomib or vorinostat.~* Participant has active Hepatitis B or C, plasma cell leukemia, or is human immunodeficiency virus (HIV) positive.~* Participant has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat + Bortezomib (Type: EXPERIMENTAL): Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
- Placebo + Bortezomib (Type: PLACEBO_COMPARATOR): Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female age ≥21 to ≤75 years.~2. Screening fasting triglyceride ≥500 milligrams (mg)/deciliters (dL) and ≤2000 mg/dL.~3. Willing to maintain current eating and exercise habits from time of signing the informed consent and for the duration of the study.~4. Participants could be taking statins and/or prescription fish oil as background therapy or not be taking any background therapy.~5. Magnetic resonance imaging - whole liver proton density fat fraction (MRI-PDFF) of ≥6% for participants screened for the Fibrate Expansion cohort.~Exclusion Criteria:~1. Uncontrolled or newly diagnosed hypertension.~2. Body mass index \>45 kilograms (kg)/meters squared (m\^2).~3. Receiving niacin, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, or supplements that could lower lipid levels.~4. Type 1 diabetes mellitus.~5. Diagnosis of Type 2 diabetes mellitus \<6 months prior to screening.~6. History of malignancy within 5 years prior to screening.~7. Participants with known lipoprotein lipase impairment or deficiency (Fredrickson Type 1), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type 3).~8. Clinically or otherwise documented cardiovascular or cerebrovascular disease.~9. Weight change ≥5% in 3 months prior to first screening visit or weight change ≥5% during screening or planning to try to lose weight during conduct of study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pegozafermin 9 mg QW (Type: EXPERIMENTAL): Participants received pegozafermin 9 mg QW as an SC injection for 8 weeks in the Main Study cohort.
- Pegozafermin 18 mg QW (Type: EXPERIMENTAL): Participants received pegozafermin 18 mg QW as an SC injection for 8 weeks in the Main Study cohort.
- Pegozafermin 27 mg QW (Type: EXPERIMENTAL): Participants received pegozafermin 27 mg QW as an SC injection for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion pegozafermin 27 mg QW groups were pooled together due to low sample size in the expansion cohort.
- Pegozafermin 36 mg Q2W (Type: EXPERIMENTAL): Participants received pegozafermin 36 mg Q2W as an SC injection for 8 weeks in the Main Study cohort.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo was injected at matching frequency per assigned cohort for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion placebo groups were pooled together due to low sample size in the expansion cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Cerebral infarction except cardiac source of embolism based on the NINDSⅢclassification~2. Neurological signs persisting≧ 1 day from onset~3. Defined onset of symptoms, and stable condition at the period of enrollment~4. CT or MRI detection of responsible site~5. age≧20~6. Systolic pressure≦180 mmHg, Diastolic pressure≦110 mmHg~7. The maximum intensity of platelet aggregation is above 15 % induced by serotonin (1µM) and epinephrine (3µM) on the day of prior to the first medication~8. Written informed consent must be obtained from the patients before enrollment into the study~Exclusion Criteria:~1. Functional outcome at randomization: Modified Rankin Scale=4, 5~2. Previous or planned for vascular surgery to cerebral infarction~3. History of intracranial hemorrhage~4. History of systemic bleeding, or other history of bleeding diathesis or coagulopathy~5. With severe complications ( renal or hepatic insufficiency, heart failure, hemopathy, and so on )~6. Treating malignant tumor~7. Pregnant or possibly pregnant women, or nursing mothers~8. History of sarpogrelate sensitivity~9. Previously entered in other clinical trials within 3 months~10. Less than 3 months since any other clinical trial~11. Judged by investigator to be unsuitable for the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group L (Type: EXPERIMENTAL): 25mg sarpogrelate
- group M (Type: EXPERIMENTAL): 50mg sarpogrelate
- group H (Type: EXPERIMENTAL): 100mg sarpogrelate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete